A safe, effective and adaptable live-attenuated SARS-CoV-2 vaccine to reduce disease and transmission using one-to-stop genome modifications

Jacob Schön(Friedrich-Loeffler-Institut), Volker Thiel(University of Bern), Nico Joël Halwe(Friedrich-Loeffler-Institut), Fabien Labroussaa(Université Claude Bernard Lyon 1), Marco P. Alves(University of Bern), Lisa Thomann(University of Bern), Angele Breithaupt(Friedrich-Loeffler-Institut), Sarah Ochsenbein(University of Bern), Demeter Túrós(University of Bern), G. Tuba Barut(University of Bern), Llorenç Grau‐Roma(Universitat Autònoma de Barcelona), Kore Schlottau(Friedrich-Loeffler-Institut), Kimberly Schmied(University of Bern), Martin Beer(Institute of Virology of the Slovak Academy of Sciences), Charaf Benarafa(University of Bern), Björn Corleis(Friedrich-Loeffler-Institut), Vladimir Cmiljanović(PIQUR Therapeutics (Switzerland)), Silvio Steiner(University of Bern), Lea Almeida(University of Bern), Joerg Jores(University of Bern), Adriano Taddeo(University of Bern), Hanspeter Stalder(University of Bern), Annika Kratzel(University of Bern), Blandina I. Oliveira Esteves(University of Bern), Claudia Wylezich(Friedrich-Loeffler-Institut), Melanie Brügger(University of Bern), Nadine Ebert(University of Bern), Lorenz Ulrich(Friedrich-Loeffler-Institut), Bettina Salome Trüeb(University of Bern), Ann Kathrin Ahrens(Friedrich-Loeffler-Institut), Étori Aguiar Moreira(University of Bern), Christelle Devisme(University of Bern), Philip V’kovski(University of Bern), Inês Berenguer Veiga(University of Bern), Tobias Britzke(Friedrich-Loeffler-Institut), Donata Hoffmann(Friedrich-Loeffler-Institut), Jana Kochmann(Friedrich-Loeffler-Institut), Jenna N. Kelly(University of Bern)
Nature Microbiology
July 12, 2024
Cited by 26


Related Papers